Sugi Predict

Sugi Predict / Compounds / SCHEMBL325632

SCHEMBL325632

SCHEMBL325632

N#Cc1cc(F)ccc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 17/20 0.50
▸ KIF11 P52732 1/20 0.44
▸ SLC22A12 Q96S37 1/20 0.44
▸ PGR P06401 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421468 1.00 AR (0.50) ARKIF11SLC22A12PGRKDM4E
SCHEMBL221383 0.83 AR (0.62) ARPGR
SCHEMBL13487588 0.82 AR (0.39) ARSLC22A12
SCHEMBL5203682 0.79 KIF11 (0.53) ARKIF11SLC22A12PGR
SCHEMBL16401745 0.79 IDO1 (0.38) ARKIF11SLC22A12KDM4EALDH1A1
SCHEMBL1996176 0.79 AR (0.53) ARKIF11SLC22A12
SCHEMBL29892139 0.79 IDO1 (0.38) ARKIF11SLC22A12KDM4EALDH1A1
SCHEMBL20455559 0.79 IDO1 (0.38) ARKIF11SLC22A12KDM4EALDH1A1
SCHEMBL663706 0.78 AR (0.43) ARKIF11SLC22A12PGR
SCHEMBL12326829 0.78 AR (0.59) ARSLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117613388-B Electrolyte and sodium ion battery 湖州超钠新能源科技有限公司 2024-05-07 — — CN claimed
CN-117613388-A Electrolyte and sodium ion battery 湖州超钠新能源科技有限公司 2024-02-27 — — CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof BAUSCH + LOMB IRELAND LIMITED (IE) 2025-10-07 — — US disclosed
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2024-09-19 — — US disclosed
CN-118108627-A Hydrogenation method for breaking fluorocarbon bonds of trifluoromethyl aromatic hydrocarbon 中国科学院大连化学物理研究所 2024-05-31 — — CN disclosed
CN-117613388-B Electrolyte and sodium ion battery 湖州超钠新能源科技有限公司 2024-05-07 — — CN disclosed
CN-117613388-A Electrolyte and sodium ion battery 湖州超钠新能源科技有限公司 2024-02-27 — — CN disclosed
EP-4313951-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-02-07 — — EP disclosed
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2023-12-19 — — US disclosed
CN-117062804-A 1, 3-substituted cyclobutyl derivatives and their use 诺华股份有限公司 2023-11-14 — — CN disclosed
US-20070082907-A1 Peroxisome proliferator activated receptor modulators ELI LILLY AND COMPANY (IN) 2007-04-12 — — US disclosed
EP-1697304-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-09-06 — — EP disclosed
CN-1703399-A Pharmaceutical compositions as dipeptidyl peptidase-IV (DPP-IV) inhibitors ABBOTT LAB (US) 2005-11-30 — — CN disclosed
US-20050215784-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2005-09-29 — — US disclosed
EP-1560811-A2 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) Abbott Laboratories (US) 2005-08-10 — — EP disclosed
WO-2005054176-A1 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-16 — — WO disclosed
US-20040259843-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2004-12-23 — — US disclosed
US-20040121964-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBOTT LABORATORIES 2004-06-24 — — US disclosed
WO-2004026822-A2 PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) ABBOTT LABORATORIES (US) 2004-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845730-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 AR 2559/4885KIF11 4205/4885SLC22A12 1493/4885
US-12435040-B2 1,3-substituted cyclobutyl derivatives and uses thereof TRPV1, TRPV3, TRPV2 AR 2559/4885KIF11 4205/4885SLC22A12 1493/4885
US-20040121964-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) DPP4, DPP3, DPP7 AR 3959/4885KIF11 4245/4885SLC22A12 2472/4885
US-20240308965-A1 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF TRPV1, TRPV3, TRPV2 AR 2559/4885KIF11 4205/4885SLC22A12 1493/4885
US-20050215784-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) DPP4, DPP3, DPP7 AR 3944/4885KIF11 4235/4885SLC22A12 2504/4885
US-20040259843-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) DPP4, DPP3, DPP7 AR 3959/4885KIF11 4245/4885SLC22A12 2472/4885
US-20070082907-A1 Peroxisome proliferator activated receptor modulators PPARG, PPARA, PPARD AR 277/4885KIF11 2068/4885SLC22A12 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.